

Phase I Trial: 323476

Submission date 10/09/2024	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 13/09/2024	Overall study status Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 20/01/2026	Condition category Other	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)

Scientific, Principal investigator

Contact name

Prof Amanda Adler

Contact details

University of Oxford, Diabetes Trial Unit
Oxford
United Kingdom
OX3 7LJ

-
enquiries@rdm.ox.ac.uk

Type(s)

Public

Contact name

Dr Information Team

Contact details

117 Charterhouse Street
London
United Kingdom
EC1M 6AA

-
info@sava.health

Additional identifiers

Integrated Research Application System (IRAS)

323476

Central Portfolio Management System (CPMS)

59146

Study information

Scientific Title

The full scientific title will be published within 30 months after the end of the trial

Study objectives

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 22/03/2024, London - Dulwich Research Ethics Committee (2nd Floor, 2 Redman Place, London, E20 1JO, United Kingdom; 0207 104 8290; dulwich.rec@hra.nhs.uk), ref: 24/LO/0134

Study design

Multi-site trial with 50 participants

Primary study design

Interventional

Study type(s)

Other

Health condition(s) or problem(s) studied

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Interventions

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date

07/08/2025

Eligibility**Key inclusion criteria**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)

Other

Healthy volunteers allowed

No

Age group

Not Specified

Sex

All

Total final enrolment

0

Key exclusion criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment

24/11/2024

Date of final enrolment

28/07/2025

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Addenbrooke's Hospital Laboratory

Addenbrookes Hospital

Hills Road

Cambridge

England

CB2 0QQ

Sponsor information

Organisation

SAVA Technologies Ltd.

Funder(s)

Funder type

Industry

Funder Name

SAVA Technologies Ltd.

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available